For the quarter ending 2026-03-31, REVB had $3,413,084 increase in cash & cash equivalents over the period. -$3,286,730 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -3,009,051 | -2,511,006 | -6,402,643 |
| Stock-based compensation expense | 470,997 | 370,166 | 225,202 |
| Non-cash lease expense | 55,699 | 18,630 | - |
| Depreciation expense | 7,203 | 5,852 | 21,206 |
| Loss on disposal of equipment | - | 0 | -11,207 |
| Change in fair value of warrant liability | - | -87 | -2,071 |
| Prepaid expenses and other current assets | 39,297 | -12,637 | 57,235 |
| Other assets | - | 30,941 | - |
| Accounts payable | 216,900 | -442,450 | 236,330 |
| Accrued expenses | -929,562 | 604,341 | -334,585 |
| Operating lease liability | 12,260 | 5,866 | - |
| Net cash used in operating activities | -3,214,851 | -1,966,992 | -6,302,589 |
| Proceeds from public offering, net-May2025Public Offering | - | 0 | 3,388,244 |
| Proceeds from warrant exercise-Class HPre Funded Warrants | - | 0 | 297 |
| Proceeds from warrant exercise-Class HCommon Stock Warrants | - | 363,000 | - |
| Purchase of property and equipment | 71,879 | - | - |
| Proceeds from warrant exercise-Warrant Inducement | - | -41,166 | 8,760,519 |
| Net cash used in investing activities | -71,879 | - | - |
| Proceeds from warrant exercise-Class HWarrants | - | - | 363,000 |
| Proceeds from warrant inducement exercises, net | 6,699,814 | - | - |
| Net cash provided by financing activities | 6,699,814 | -41,166 | 12,512,060 |
| Net (decrease) increase in cash and cash equivalents | 3,413,084 | -2,008,158 | 6,209,471 |
| Cash and cash equivalents at beginning of period | 10,700,331 | 12,708,489 | 6,499,018 |
| Cash and cash equivalents at end of period | 14,113,415 | 10,700,331 | 12,708,489 |
REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC. (REVB)